Earnings Releases

NI Holdings, Inc. reported financial results for the quarter ended March 31, 2024.

“On May 9, 2024, the Company issued a press release announcing its financial results for the quarter ended March 31, 2024.”

SenesTech, Inc. reported first quarter ended March 31, 2024 results: revenue $415,000, net income $1.8 million.

“EPA-registered Rat Birth Control ® products today announced financial results for the first quarter of 2024. Recent Highlights • Record quarterly revenues during Q1 2024 of $415,000, an increase of 78% compared to Q1 2023. • EvolveTM, formulated especially for the control of rat fertility and launched at the beginning of the year, has quickly become the”

Hilton Grand Vacations Inc. reported financial results for quarter ended March 31, 2024.

“On May 9, 2024, Hilton Grand Vacations Inc. (the “Company”) issued a press release announcing the results of the Company’s operations for the quarter ended March 31, 2024.”

RAPT Therapeutics, Inc. reported the quarter ended March 31, 2024 results: net income Net loss for the first quarter of 2024 was $30.5 million.

“RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based therapeutics company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology, today reported financial results for the first quarter ended March 31, 2024.”

ARS Pharmaceuticals, Inc. reported financial results for the quarter ended March 31, 2024.

“On May 9, 2024, ARS Pharmaceuticals, Inc. (the “Company”) announced its financial results for the quarter ended March 31, 2024 in the press release attached hereto as Exhibit 99.1 and incorporated herein by reference.”

YETI Holdings, Inc. updated its first quarter ended March 30, 2024 guidance (raised).

“On May 9, 2024, YETI Holdings, Inc. (the “Company”) issued a press release announcing its 2024 fiscal first quarter financial results. The press release is being furnished with this Current Report on Form 8-K as Exhibit 99.1 and is incorporated herein by reference.”

US Foods Holding Corp. reported financial results for the fiscal first quarter ended March 30, 2024.

“On May 9, 2024, US Foods Holding Corp. issued a press release announcing its financial results for the fiscal first quarter ended March 30, 2024.”

Phunware, Inc. reported first quarter ended March 31, 2024 results: revenue $0.9 million, net income $(2.3) million, EPS $(0.33).

“to make a global difference in mobile.” First Quarter 2024 Financial Results - A Foundation to Build Upon Statement of Income (Loss) • Net revenues for the quarter totaled $0.9 million, exceeding the Company’s internal Q1 2024 plan by 5% • Gross margin was 56.9% up from 5.4% in Q1 2023 • Net loss decreased to $(2.3) million from $(4.3) million in Q1 2023 • Net”

Organogenesis Holdings Inc. reported first quarter ended March 31, 2024 results: revenue $110.0 million, net income $2.1 million, EPS $(0.02) per share. Guidance reaffirmed.

“Surgical & Sports Medicine markets, today reported financial results for the first quarter ended March 31st, 2024. First Quarter 2024 Financial Results Summary: • Net revenue of $110.0 million for the first quarter of 2024, an increase of $2.3 million compared to net revenue of $107.6 million for the first quarter of 2023. Net revenue for the first quarter of 2024”

Bloom Energy Corp reported first quarter ended March 31, 2024 results: revenue $235.3 million, net income $(57,524), EPS $(0.25). Guidance reaffirmed.

“JOSE, Calif., May 9, 2024 — Bloom Energy Corporation (NYSE: BE) reported today its financial results for the first quarter ended March 31, 2024. The company reported revenue of $235.3 million for the first quarter of 2024. First Quarter Highlights • Revenue of $235.3 million in the first quarter of 2024, a decrease of 14.5% compared to $275.2 million in the first”

Q32 Bio Inc. reported the quarter ended March 31, 2024 results: net income $1.0 million, EPS $1.03 basic net income per share and ($6.33) diluted net loss per share.

“Q32 Bio Inc. announced its financial results for the quarter ended March 31, 2024”

Amylyx Pharmaceuticals, Inc. reported financial results for first quarter ended March 31, 2024.

“On May 9, 2024, Amylyx Pharmaceuticals, Inc. (the “Company”) issued a press release announcing its financial results for the fiscal quarter ended March 31, 2024.”

Crinetics Pharmaceuticals, Inc. reported the first quarter ended March 31, 2024 results: revenue $0.6 million, net income $66.9 million.

“of $5.6 million. • Net loss for the three months ended March 31, 2024, was $66.9 million, compared to a net loss of $46.0 million for the same period in 2023. • Revenues were$0.6 million for the three months ended March 31, 2024, compared to $2.7 million for the same period in 2023. Revenues were derived from licensing arrangements for our paltusotine product”

Xometry, Inc. reported first quarter ended March 31, 2024 results: revenue $123 million, net income $16.6 million, EPS $(0.34) per diluted share.

“expressly stated in such filing. --- EX-99.1 (EX-99.1) --- EX-99.1 Exhibit 99.1 Xometry Reports First Quarter 2024 Results • Q1 revenue increased 16% year-over-year to $123 million driven by marketplace growth of 24% year-over-year. • Q1 gross profit increased 22% year-over-year driven by 37% growth in marketplace gross profit. Q1 marketplace gross margin”

Gritstone bio, Inc. reported financial results for first quarter ended March 31, 2024.

“On May 9, 2024, Gritstone bio, Inc. issued a press release announcing its financial results for the first quarter ended March 31, 2024 and provided a business update.”

Verona Pharma plc reported financial results for the first quarter ended March 31, 2024.

“Verona Pharma plc announced its financial results for the quarter ended March 31, 2024.”

Cronos Group Inc. reported first quarter ended March 31, 2024 results: revenue $25.3 million, net income $ (2,484).

“Group Reports 2024 First Quarter Results Industry-leading balance sheet with $855 million in cash and cash equivalents Net revenue in Q1 2024 increased by 30% year-over-year to $25.3 million Spinach ® was top-3 in retail sales in Canada in the flower, edible, and vape categories in Q1 2024 Launched PEACE NATURALS ® brand in the United Kingdom in May 2024 TORONTO, May”

Intellia Therapeutics, Inc. reported financial results for first quarter ended March 31, 2024.

“On May 9, 2024, Intellia Therapeutics, Inc. announced its financial results and business updates for the quarter ended March 31, 2024.”

Priority Technology Holdings, Inc. reported first quarter 2024 results: revenue $205.7 million.

“First Quarter 2024 Compared with First Quarter 2023 Financial highlights of the first quarter of 2024 compared with the first quarter of 2023, are as follows 1 : • Revenue of $205.7 million increased 11.2% from $185.0 million • Adjusted gross profit (a non-GAAP measure 2 ) of $76.4 million increased 21.2% from $63.1 million • Adjusted gross profit margin (a non-GAAP”

4D Molecular Therapeutics, Inc. reported financial results for the three months ended March 31, 2024.

“4D Molecular Therapeutics, Inc. (“4DMT”) announced its financial results for the three months ended March 31, 2024.”

Kezar Life Sciences, Inc. reported first quarter ended March 31, 2024 results: net income $21.7 million, EPS $0.30 per basic and diluted common share.

“Net loss for the first quarter of 2024 was $21.7 million, or $0.30 per basic and diluted common share”

Monopar Therapeutics reported first quarter ended March 31, 2024 results: net income $1.6 million, EPS $0.10 per share.

“Net loss for the first quarter of 2024 was $1.6 million or $0.10 per share compared to net loss of $2.4 million or $0.19 per share for the first quarter of 2023.”

Cue Biopharma, Inc. reported first quarter 2024 results: revenue $1.7 million, net income Net loss $(12.3) million, EPS $(0.25) per share.

“disease positions us well to potentially deliver value creation for our shareholders.” First Quarter 2024 Financial Results The Company reported collaboration revenue of $1.7 million and $0.2 million for the three months ended March 31, 2024 and 2023, respectively. The increase was due to revenue earned from our Collaboration and Option Agreement with Ono”

Sterling Check Corp. reported for the first quarter ended March 31, 2024 results: revenue $186.0 million, net income $(7,955), EPS $(0.09) per diluted share.

“results for the first quarter ended March 31, 2024. First Quarter 2024 Highlights All results compared to prior-year period. • Revenues increased 3.8% year-over-year to $186.0 million. Organic constant currency revenue decreased 4.9% and inorganic revenue growth was 8.7%. Organic revenue growth included growth of 11% year-over-year from the combination of new”

vTv Therapeutics Inc. reported financial results for the first quarter ended March 31, 2024.

“On May 9, 2024, vTv Therapeutics Inc. issued a press release to announce its financial results for the fiscal period ended March 31, 2024.”

MetaVia Inc. reported financial results for first quarter ended March 31, 2024.

“On May 9, 2024, NeuroBo Pharmaceuticals, Inc. (the “ Company ”) issued a press release announcing its financial results for the first quarter ended March 31, 2024 and providing a corporate strategic update.”

Health Catalyst, Inc. reported the quarter ended March 31, 2024 results: revenue $74.7 million.

“today reported financial results for the quarter ended March 31, 2024. “For the first quarter of 2024, I am pleased by our strong financial results, including total revenue of $74.7 million and Adjusted EBITDA of $3.4 million, with these results beating the mid-point of our quarterly guidance on each metric. This financial performance demonstrates our ability to”

Spyre Therapeutics, Inc. reported financial results for the first quarter ended March 31, 2024.

“issued a press release announcing its financial results for the first quarter ended March 31, 2024”

National Western Life Group, Inc. reported the quarter ended March 31, 2024 results: revenue $197.6 million, net income $73.6 million, EPS $20.82 per diluted share.

“Common Stock for the first quarter of 2023. The Company's book value per share as of March 31, 2024 was $686.73. The Company's reported revenues for the quarter increased 29% to $197.6 million from $152.6 million in the first quarter of 2023. Equity market performance during the 2024 first quarter helped to increase the realized and unrealized gains on derivative”

Wave Life Sciences Ltd. reported financial results for the quarter ended March 31, 2024.

“On May 9, 2024, Wave Life Sciences Ltd. (the “Company”) announced its financial results for the quarter ended March 31, 2024.”

Commerce.com, Inc. reported first quarter ended March 31, 2024 results: revenue $80.4 million.

“BigCommerce Announces First Quarter 2024 Financial Results First Quarter Total Revenue of $80.4 Million, an Increase of 12% Versus Prior Year.”

Babcock & Wilcox Enterprises, Inc. reported the quarter ended March 31, 2024 results: revenue $207.6 million, net income Net loss of $15.8 million, EPS Loss per share of $0.22. Guidance raised.

“reference in such filing. --- EX-99.1 (EX-99.1) --- News Release Babcock & Wilcox Enterprises Reports First Quarter 2024 Results • Exceeded expectations with Revenue of $207.6 million and Operating Income of $4.3 million • Increased Full Year 2024 Adjusted EBITDA target range to $105.0 million to $115.0 million, excluding BrightLoop TM and ClimateBright TM”

CaliberCos Inc. reported first quarter ended on March 31, 2024 results: revenue $23.0 million, net income Net loss attributable to Caliber of $3.8 million, EPS $0.18 per diluted share.

“First Quarter 2024 Financial Highlights (compared to first quarter 2023) • Total revenue of $23.0 million, a 22.3% decrease • Platform revenue of $4.7 million, a 25.6% decrease – Asset management revenue of $4.6 million, a 16.1% increase – Performance allocations of $0.2 million, related to the sale of land in Johnstown, Colorado • Net loss attributable to Caliber of $3.8 million, or $0.18 per diluted share, compared to net loss attributable to Caliber of $1.2 million or $0.07 per diluted share • Caliber Adjusted EBITDA loss of $1.7 million, compared to Caliber Adjusted EBITDA of $1.0 million • Fair value assets under management (“FV AUM”) of $766.7 million, a 3.4% increase, primarily due to the L.T.D.”

Evolent Health, Inc. reported the quarter ended March 31, 2024 results: revenue $639.7 million, net income $(25.2) million. Guidance raised.

“Evolent Announces First Quarter 2024 Results • Revenue of $639.7 million, an increase of $212.0 million or 49.6%, from the three months ended March 31, 2023. • Net loss attributable to common shareholders of Evolent Health, Inc. of $(25.2) million and a net loss margin of (3.9)%.”

ALPINE IMMUNE SCIENCES, INC. reported financial results for first quarter ended March 31, 2024.

“On May 9, 2024, Alpine Immune Sciences, Inc. issued a press release reporting its financial results for the three months ended March 31, 2024.”

CS Disco, Inc. reported first quarter ended March 31, 2024 results: revenue $35.6 million, net income $10.6 million, EPS $(0.34) per diluted share. Guidance initiated.

“DISCO Announces First Quarter 2024 Financial Results Total Revenue of $35.6 Million, A Year over Year Increase of 7%”

ZIPRECRUITER, INC. reported the quarter ended March 31, 2024 results: revenue $122.2 million, net income ($6.5) million.

“ZipRecruiter Announces First Quarter 2024 Results Quarterly revenue of $122.2 million Quarterly net loss of ($6.5) million”

Natera, Inc. reported first quarter ended March 31, 2024 results: revenue $367.7 million, net income net loss of $67.6 million, EPS ($0.56) per diluted share.

“First Quarter Ended March 31, 2024 Financial Results Total revenues were $367.7 million in the first quarter of 2024 compared to $241.8 million in the first quarter of 2023, an increase of 52.1%. The increase in total revenues was driven primarily by a 53.4% increase in product revenues, which were $364.7 million in the first quarter of 2024 compared to $237.8 million in the first quarter of 2023. The increase in product revenues was primarily driven by an increase in volume, as well as average selling price improvements. Natera processed approximately 735,800 tests in the first quarter of 2024, including approximately 718,700 tests accessioned in its laboratory, compared to approximately 626,200 tests processed, including approximately 607,700 tests accessioned in its laboratory, in the first quarter of 2023. In the first quarter of 2024, Natera recognized revenue on approximately 679,400 tests for which results were reported to customers in the period (tests reported), including appr”

Pangaea Logistics Solutions Ltd. reported three months ended March 31, 2024 results: revenue $104.7 million, net income $11.7 million, EPS $0.25 per diluted share.

“million in May 2024 For the first quarter ended March 31, 2024, Pangaea reported non-GAAP adjusted net income of $6.6 million, or $0.14 per diluted share, on total revenue of $104.7 million. First quarter TCE rates increased 23% on a year-over-year basis, while total shipping days, which include both voyage and time charter days, declined 7% to 3,685 days, when”

RECURSION PHARMACEUTICALS, INC. reported financial results for first quarter ending March 31, 2024.

“On May 9, 2024, the Company issued a press release announcing its results of operations and financial condition for the first quarter March 31, 2024.”

Atara Biotherapeutics, Inc. reported financial results for first quarter 2024.

“Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported financial results for the first quarter 2024, recent business highlights, and key upcoming milestones for 2024.”

Avidity Biosciences, Inc. reported financial results for first quarter ended March 31, 2024.

“On May 9, 2024, Avidity Biosciences, Inc. issued a press release announcing its financial results for the quarter and year ended March 31, 2024.”

Metallus Inc. reported first quarter of 2024 results: revenue $321.6 million, net income $24.0 million, EPS $0.52 per diluted share.

“be expressly set forth by specific reference in such a filing. --- EX-99.1 (EX-99.1) --- EX-99.1 Exhibit 99.1 Metallus Announces First-Quarter 2024 Results • Net sales of $321.6 million with net income of $24.0 million and adjusted EBITDA (1) of $43.4 million • Operating cash flow of $33.4 million with ending cash and cash equivalents of $278.1 million •”

Gold.com, Inc. reported fiscal third quarter ended March 31, 2024 results: EPS $0.21 per diluted share.

“A-Mark Precious Metals Reports Fiscal Third Quarter 2024 Results Q3 FY 2024 Diluted Earnings Per Share of $0.21”

OXBRIDGE RE HOLDINGS Ltd reported the three months ended March 31, 2024 results: revenue $549,000, net income net loss of $905,000, EPS ($0.15) per basic and diluted common share.

“For the three months ended March 31, 2024, the Company generated a net loss of $905,000 or ($0.15) per basic and diluted common share compared to a net income of $142,000 or $0.02 per basic and diluted common share in the first quarter of 2023. The decrease is primarily due to the negative change in the fair value of equity securities and investments during the quarter ended March 31, 2024 when compared with the prior period. 1 Net premiums earned for the three months ended March 31, 2024 increased to $549,000 from $0 in the prior year’s first quarter .”

Matinas BioPharma Holdings, Inc. reported the three months ending March 31, 2024 results: revenue no revenue for the first quarter of 2024, net income net loss for the first quarter of 2024 was $5.8 million, or $0.03 per share, EPS $0.03 per share.

“Matinas BioPharma Holdings, Inc . (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology, reports financial results for the three months ending March 31, 2024 and provides a business update.”

Xenon Pharmaceuticals Inc. reported financial results for the first quarter ended March 31, 2024.

“On May 9, 2024, Xenon Pharmaceuticals Inc. (the “Company”) announced via press release the Company’s financial results for the three months ended March 31, 2024.”

Life360, Inc. reported the quarter ended March 31, 2024 results: revenue $78.2 million, net income $(9.8) million. Guidance reaffirmed.

“Total Q1’24 revenue of $78.2 million, a YoY increase of 15%”

Installed Building Products, Inc. reported the first quarter ended March 31, 2024 results: revenue $692.9 million, net income $55.9 million, EPS $1.97 per diluted share.

“For the first quarter of 2024, net revenue was $692.9 million”

Vital Farms, Inc. reported first quarter ended March 31, 2024 results: revenue $147.9 million, net income $19.0 million, EPS $0.43. Guidance raised.

“Vital Farms Reports First Quarter 2024 Financial Results Record First Quarter Net Revenue of $147.9 million, up 24.1% versus Prior Year Period Raises Fiscal Year 2024 Outlook”